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SHORT COMMUNICATION
Evaluation of the synthetic somatostatin analogue SMS 201-995 in
patients with hypoglycaemia associated with hepatocellular carcinoma
B.I. Joffe, M.C. Kew, V.R. Panz, W.J. Kalk, R. Shires, J. Wing & H.C. Seftel
Department of Medicine, University of the Witwatersrand Medical School, York Road, Parktown 2193, Johannesburg, South
Africa.
Hypoglycaemia related to extrapancreatic neoplasms is well
documented but its pathogenesis remains unclear (Kahn,
1980). One possible explanation is the production by the
tumour of an 'insulin-like' polypeptide (e.g., insulin-like
growth factor or IGF), which has been found in the serum
of such cases by some workers (Gorden et al., 1981;
Daughaday et al., 1981), but not by others (Joffe et al.,
1978; Zapf et al., 1981).
Irrespective of its pathophysiology, tumour hypoglycaemia
is extremely difficult to manage. One therapeutic approach
that does not appear to have been formally evaluated is the
use of somatostatin, which is capable of suppressing many
polypeptide hormones, including IGF (Editorial, 1985).
In the present investigation we have therefore assessed
the possible therapeutic role of the synthetic somatostatin
analogue SMS 201-995 (Sandoz, Basel, Switzerland) in 4
patients with life-threatening, type B hypoglycaemia caused
by hepatocellular carcinoma. Glucoregulatory hormonal
responses were evaluated at the same time.
Four male South African Black patients with biopsy-
proven primary hepatocellular carcinoma and severe con-
tinuous or recurrent hypoglycaemia were investigated. Their
ages ranged from 24-50 years. All were nonobese, but not
emaciated or dehydrated. None had received chemotherapy
at the time of study. The hypoglycaemia was considered to
be of the type B variety (i.e., severe hypoglycaemia occurring
early in the course of the disease, without extensive hepatic
infiltration by tumour and requiring continuous or repeated
i.v. dextrose infusions to avoid neuroglycopenia) (McFadzean
& Yeung, 1969). The ethical aspects of the study were
approved by the Committee for Research on Human
Subjects of the University of Witwatersrand, Johannesburg.
Three of the 4 patients were on continuous i.v. dextrose
infusions, which were changed to normal saline on the
morning of study. The fourth patient, with intermittent
hypoglycaemia, was studied after a 6h early morning fast.
After confirming the presence of biochemical hypoglycaemia
(venous blood glucose below 3.0mmol -1 on a bed-side
Haemoglucotest - Model B Glucocheck reading), each sub-
ject had a second saline infusion inserted at the antecubital
fossa of the opposite arm for subsequent SMS 201-995
infusions.
Two basal venous blood samples were then collected,
10min apart, after which SMS 201-995 was administered by
an initial i.v. bolus injection followed by a continuous i.v.
infusion over 3h. In the first 2 patients the dosages used
were a 50Mg bolus and then 50pgh-1. These amounts of
somatostatin were doubled in the last 2 cases because of an
inability to raise the blood glucose concentration. Repeat
venous blood samples were taken at half hourly intervals for
bed-side blood glucose determinations, with an additional
aliquot collected into a fluoride tube for later laboratory
confirmation. At hourly intervals extra blood was collected
into chilled heparin-trasylol tubes which were centrifuged
within 2h and the supernatant plasma stored at -20°C until
analysis some weeks later. If a patient showed evidence of
increasing neuroglycopenia at any sampling time, an i.v.
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bolus of 10ml of 50% dextrose solution was injected
immediately after sampling. On completing the protocol, the
3 patients who were previously receiving continuous i.v.
dextrose returned to their original therapy.
Plasma glucose was measured in duplicate on a Beckman
glucose analyzer employing a glucose oxidase method and
these figures were taken as definitive glucose results. Com-
mercial radioimmunoassay kits were employed to measure
the plasma concentrations of the following hormones: insulin
(Pharmacia Diagnostics AB, Sweden); somatomedin C/IGF1
(CIS, France); growth hormone (GH) (Serono Diagnostics,
Switzerland) and pancreatic glucagon (Serono Diagnostics,
Switzerland). All plasma samples were assayed in single runs
to avoid inter-assay variability; the intra-assay coefficients
of variation were less than 10% for all hormonal
measurements.
Basal data represent the mean of the 2 pre-infusion results.
The significance of changes from basal were assessed by the
paired t test.
Table I outlines the plasma glucose, insulin and somato-
medin C responses after administering SMS 201-995 to the 4
patients with hepatocellular carcinoma. In no patient did the
post SMS 201-995 plasma glucose concentrations rise above
basal, apart from 2 samples taken soon after an i.v. dextrose
bolus. Plasma insulin levels were appropriately depressed in
the first 2 subjects in whom this hormone was assayed, while
somatomedin C was subnormal both before and during SMS
201-995 infusion in all 4 cases.
Table II indicates the effects of SMS 201-995 infusion on
the counterregulatory hormones GH and pancreatic gluca-
gon. Basal GH concentrations were raised in two and
normal in the other 2 cases. The basal pancreatic glucagon
concentration was remarkably low in one patient (no 4) and
within the normal range in the rest. Nevertheless, both
hormones were consistently suppressed despite the continu-
ing hypoglycaemia. For GH the mean + s.e. nadir during
SMS 201-995 infusion was 1.0+0.3pgl-1 compared with a
basal level of 6.8+3.9:ugl-1 (P<0.1). For glucagon the
corresponding levels were 29+9ng 1 - I versus 62+21 ngI'
(P<0.1).
The symptomatic treatment of tumour hypoglycaemia has
included the frequent administration of carbohydrate-rich
foods or parenteral glucose; glucocorticoids in pharmaco-
logic doses, and diazoxide. All these measures are largely
ineffectual and only reduction of the tumour mass may
induce a remission (Cryer, 1985). Somatostatin, which can
ameliorate the hypoglycaemia associated with insulinomas
(Long et al., 1979), was used on the assumption that it might
suppress the secretion of an insulin-like polypeptide by the
hepatic tumour issue.
The short-term failure of this mode of therapy can be
interpreted in several ways. One possibility is that the
hypoglycaemia was not due to the production of an insulino-
mimetic peptide. Somatomedin C/IGF1 concentrations were
low, and although other insulin-like growth factors were not
measured, Zapf et al. (1981) did not find them elevated. A
second, and more likely, postulate is that the production of
an insulin-like substance by the tumour cells was autono-
mous and not suppressible by infusing SMS 201-995. Related
to this is the relatively selective nature of this synthetic
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Table I Plasma glucose, insulin and somatomedin C responses to SMS 201-995 administration in 4 patients with
hypoglycaemia associated with hepatocellular carcinoma
Glucose (mmoll-1) Insulin (mUl-1) Somatomedin C (nmoll-1)
Jh 2h 3h Ihr 2h 3h Ih 2h 3h
Patient Age post post post post post post post post post
no. (yr) Basal SMS SMS SMS Basal SMS SMS SMS Basal SMS SMS SMS
1 24 2.0 1.2 2.3a 1.1 2.1 2.1 2.0 2.1 2.9 2.3 2.3 2.8
2 50 1.5 2.7a 1.3 1.5 2.7 3.5 2.6 2.7 2.9 2.3 4.0 -
3 30 2.8 2.1 2.3 - - - - - 3.7 5.5 4.5 -
4 27 2.2 1.7 2.0 - - - - - 3.5 4.2 3.8 -
Normal adult fasting range 3.4-7.2 5.0-25.0 9.1-46.0
aSoon after the i.v. administration of 10ml 50% dextrose; - not determined.
Table II Plasma GH and pancreatic glucagon responses to SMS 201-995 administration in 4
patients with hypoglycaemia associated with hepatocellular carcinoma
GH (,utg11) Pancreatic glucagon (ngl-1)
Patient Ih post 2h post 3h post Jh post 2h post 3h post
no. Basal SMS SMS SMS Basal SMS SMS SMS
1 18.2 6.0 3.3 2.6 115 52 42 49
2 0.7 0.2 0.2 0.3 74 43 41 -
3 5.8 0.5 2.9 - 44 27 31 -
4 2.6 0.5 0.5 - 15 4 5 -
Normal adult fasting range 0-5.0 50-250
- not determined.
somatostatin analogue in inhibiting GH, rather than insulin
or glucagon secretion (Bauer et al., 1982). Further studies
using the native form of somatostatin might be of interest.
The low basal pancreatic glucagon concentration noted in
one of the 4 subjects was an incidental finding that has,
however, been commented on before in tumour hypo-
glycaemia (Silbert et al., 1976). Even in the other 3 hepa-
toma patients in whom basal glucagon levels were normal, a
relatively impaired response could be considered likely in
view of the co-existent hypoglycaemia. The same argument
would also apply to the normal baseline GH levels in 2 of
the 4 subjects. As in the previous report, the explanation for
this defect remains unclear.
In conclusion the present investigation has shown that
SMS 201-995 is ineffective in the symptomatic management
of patients with hepatocellular carcinoma and severe tumour
hypoglycaemia, which does not appear to be associated with
elevated plasma somatomedin C activity.
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